Dudediligence.

Gain Therapeutics, Inc

GANXNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Net income, by quarter
−$4.5MSep ’24−$3.8MDec ’24−$4.5MMar ’25−$5.8MJun ’25−$5.3MSep ’25−$4.5MDec ’25−$5.6MMar ’26−$4.7MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$133,928$132,640$55,180none on filenone on file
Operating income−$13.8M−$17.8M−$22.3M−$20.4M−$18.7M
Net income−$13.9M−$17.6M−$22.3M−$20.4M−$20.2M
Operating cash flow−$12.4M−$14.7M−$18.9M−$18.9M−$18.5M
Free cash flow−$12.5M−$14.8M−$18.9M−$18.9Mnone on file
Cash$36.9M$7.3M$11.8M$10.4M$20.8M
Debt$694,294$603,393$567,850$438,504$400,953
Shares outstanding11.9M11.9M16.2M27.1M42.1M